In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Internet Economy; Biotech Style

Executive Summary

Euphoria reigned at the Chase H&Q annual health care conference. Biotechs that seemed unable to buy an audience last year presented to rooms so crowded that breathing itself was difficult. To some extent, the biotechs, particularly the genomics companies, were benefiting from the rotation of investors out of the Internet. But something else was afoot: the Internet way of valuing companies had come to biotech. In particular, the biotechs are no longer being valued according to some basic earnings model, but--like the Internet plays--on their potential to dominate their niches, and then use their financial power, as reflected in their share prices, to consolidate to themselves other and harder assets.

You may also be interested in...



FDA Details Alternatives For COVID-19 Test Supplies

The US agency has released a document explaining what COVID-19 testing supplies may be substituted.

Curecumin Piques US Consumers’ Interest; UK Curiosity Grows For Omega-3, Survey Shows

Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.

AstraZeneca Links With Accent To Target RNA-Modifying Proteins

AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.

Topics

Related Companies

UsernamePublicRestriction

Register

CO200859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel